Butyrate
Sodium/Calcium Butyrate
Short-chain fatty acid postbiotic that feeds gut lining cells, reduces inflammation, and supports the gut-brain axis.
Butyrate is a short-chain fatty acid naturally produced when gut bacteria ferment fiber. It's the primary fuel for colonocytes (colon cells), maintains gut barrier integrity, has anti-inflammatory effects, and supports the gut-brain axis. Supplemental butyrate bypasses the need for fiber fermentation, directly supporting gut health.
Mechanisms of Action
Colonocyte Fuel
Primary energy source for colon cells
HDAC Inhibition
Epigenetic anti-inflammatory effects
Gut Barrier Support
Strengthens tight junctions
Recommended Dose
300-600mg sodium/calcium butyrate, 2-3x daily
Optimal Timing
- With meals
- Spread throughout day
Take with food
Best Form
Enteric-coated sodium or calcium butyrate
Alternatives: Tributyrin (butyrate precursor), Sodium butyrate capsules
Enteric coating delivers more butyrate to the colon. Tributyrin may provide sustained release.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Taking with food reduces GI discomfort. Enteric coating helps delivery to colon.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Gut Healing
Improved gut barrier integrity
Reduced Gut Inflammation
Lower intestinal inflammation
May be beneficial; work with gastroenterologist
Who Should NOT Take This
- Known allergy or hypersensitivity to Butyrate or related compounds
Drug Interactions
Both affect similar pathways; may alter drug metabolism
May affect hepatic cytochrome P450 enzyme activity
Possible Side Effects
Tip: Take with food; use enteric-coated
Tip: Enteric coating reduces this
Warnings
- Strong odor is normal
- Enteric coating recommended for colon delivery
Top studies from 40+ peer-reviewed papers
Nikolova VL et al. • JAMA psychiatry (2021)
“This systematic review and meta-analysis found that gut microbiota perturbations were associated with a transdiagnostic pattern with a depletion of certain anti-inflammatory butyrate-producing bacteria and an enrichment of pro-inflammatory bacteria in patients with depression, bipolar disorder, schizophrenia, and anxiety.”
Key Findings:
- There was a small decrease in phylogenetic diversity (SMD = -0.24; 95% CI, -0.47 to -0.001) and no significant differences in Shannon and Simpson indices.
- Published in JAMA psychiatry (2021)
- Further research warranted to confirm findings
So D et al. • The American journal of clinical nutrition (2018)
“Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.”
Key Findings:
- Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
- Further research is required to better understand the role of individual fiber types on the growth of microbes and the overall gut microbial community.
- This review was registered at PROSPERO as CRD42016053101.
Ma T et al. • Cell reports. Medicine (2025)
“All rights reserved.”
Key Findings:
- A randomized, double-blind, placebo-controlled crossover trial involving 110 adults with chronic constipation (Rome IV criteria) demonstrates that a 3-week Probio-Eco intervention significantly improves constipation symptoms, stool straining, and worry scores.
- These findings highlight the comprehensive efficacy of Probio-Eco and provide robust evidence for its clinical application in constipation management.
- This study was registered at Chinese Clinical Trial Registry (ChiCTR2100054376).Copyright © 2025 The Authors.
- Published by Elsevier Inc.
Gao M et al. • Translational psychiatry (2023)
“This meta-analysis examined the effects of Butyrate.”
Key Findings:
- A random-effects model with restricted maximum-likelihood estimator was used to synthesize the effect size (assessed by standardized mean difference [SMD]) across studies.
- In subgroup analyses with regional variations(east/west) as a predictor, patients who were in the West had a lower Chao1 level (SMD -0.42[-0.74 to -0.10]).
- Subgroup meta-analysis showed Firmicutes level was decreased in patients with depressive disorder who were medication-free (SMD -1.54[-2.36 to -0.72]), but Bacteroidetes level was increased (SMD -0.90[0.07 to 1.72]).
- In the meta-regression analysis, six variables cannot explain the 100% heterogeneity of the studies assessing by Chao1, Shannon index, Firmicutes, and Bacteroidetes.
Bahji A et al. • Journal of addiction medicine (2022)
“The current meta-analyses provide evidence that several medications for AUDs are effective and safe and encourage the expanded use of these medications in the clinical setting.”
Key Findings:
- Nefazodone (RR = 2.11; 95% CI, 1.42-3.13), aripiprazole (RR = 1.97; 95% CI, 1.36-2.88), carbamazepine (RR = 1.85; 95% CI, 1.03-3.32), and nalmefene (RR = 1.17; 95% CI, 1.01-1.35) were associated with the most dropouts.
- Baclofen (RR = 0.83; 95% CI, 0.70-0.97) and pregabalin (RR = 0.63; 95% CI, 0.43-0.94) caused fewer dropouts than placebo.
- Nalmefene (RR = 3.26; 95% CI, 2.34-4.55), fluvoxamine (RR = 3.08; 95% CI, 1.59-5.94), and topiramate (RR=2.18; 95% CI, 1.36-3.51) caused more dropouts from adverse events over placebo.
- For reduced heavy drinking, disulfiram (RR = 0.19; 95% CI, 0.10-0.35), baclofen (RR = 0.72; 95% CI, 0.57-0.91), acamprosate (RR = 0.78; 95% CI, 0.70-0.86), and oral naltrexone (RR = 0.81; 95% CI, 0.73-0.90) were efficacious against placebo.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.